We are live on ! Find out more
COLL icon

Collegium Pharmaceutical
COLL

178 hedge funds and large institutions have $843M invested in Collegium Pharmaceutical in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 63 increasing their positions, 70 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1.19% less ownership

Funds ownership: 114.62% → 113.43% (-1.2%)

10% less capital invested

Capital invested by funds: $936M → $843M (-$92.9M)

10% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 70

10% less funds holding

Funds holding: 198 → 178 (-20)

56% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 36

91% less call options, than puts

Call options by funds: $122K | Put options by funds: $1.29M

Holders
178
Holders Change
-20
Holders Change %
-10.1%
% of All Funds
2.79%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
16
Increased
63
Reduced
70
Closed
36
Calls
$122K
Puts
$1.29M
Net Calls
-$1.17M
Net Calls Change
+$1.8M

Top Buyers

1
Victory Capital Management
Victory Capital Management
Texas
+$15.5M
2
Pacer Advisors
Pacer Advisors
Pennsylvania
+$7.65M
3
BlackRock
BlackRock
New York
+$6.05M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$4.68M
5
RCMNY
Rubric Capital Management (New York)
New York
+$3.42M

Top Sellers

1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$6.9M
2
Millennium Management
Millennium Management
New York
-$5.53M
3
CSS
Cubist Systematic Strategies
Connecticut
-$4.7M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$4.59M
5
IECM
Intrinsic Edge Capital Management
Illinois
-$3.88M
Name Holding Trade Value Shares
Change 		Change in
Stake
Arrowstreet Capital
26
Arrowstreet Capital
Massachusetts
$8M +$1.35M +59,330 +19%
Two Sigma Investments
27
Two Sigma Investments
New York
$7.86M +$146K +6,413 +2%
APM
28
Avidity Partners Management
Texas
$7.61M -$713K -31,400 -8%
Millennium Management
29
Millennium Management
New York
$7.33M -$5.53M -243,388 -42%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$6.88M -$123K -5,424 -2%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$6.65M +$3.01M +132,600 +75%
TC
32
Tejara Capital
United Kingdom
$6.55M +$1.07M +47,228 +18%
Charles Schwab
33
Charles Schwab
California
$6.35M +$192K +8,447 +3%
LSV Asset Management
34
LSV Asset Management
Illinois
$5.82M +$677K +29,800 +12%
SDIC
35
South Dakota Investment Council
South Dakota
$5.35M – – –
Goldman Sachs
36
Goldman Sachs
New York
$4.57M +$2.17M +95,786 +82%
Loomis, Sayles & Company
37
Loomis, Sayles & Company
Massachusetts
$4.43M +$4.68M +206,189 New
HIM
38
Hillsdale Investment Management
Ontario, Canada
$3.61M -$150K -6,600 -4%
FP
39
Foundry Partners
Minnesota
$3.45M +$547K +24,108 +18%
Assenagon Asset Management
40
Assenagon Asset Management
Luxembourg
$3.29M -$2.4M -105,625 -41%
SEI Investments
41
SEI Investments
Pennsylvania
$3.16M -$246K -10,855 -7%
LPL Financial
42
LPL Financial
California
$3.05M -$372K -16,393 -10%
MOACM
43
Mutual of America Capital Management
New York
$2.77M -$216K -9,493 -7%
Ameriprise
44
Ameriprise
Minnesota
$2.72M -$101K -4,431 -3%
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$2.4M -$750K -33,048 -23%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$2.34M +$148K +6,513 +6%
JP Morgan Chase
47
JP Morgan Chase
New York
$2.34M -$414K -18,247 -14%
Voloridge Investment Management
48
Voloridge Investment Management
Florida
$2.28M -$413K -18,178 -15%
PCM
49
Penn Capital Management
Pennsylvania
$2.26M +$2.39M +105,359 New
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$2.26M -$934K -41,148 -28%
1
2
3 4 5

COLL Hedge Fund Activity: Q2 2023 in Review

178 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2023, worth a combined $843M — down 9.9% from $936M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of COLL and 16 opened new positions — a net loss of 20 holders — while 70 trimmed existing stakes and 63 added.

The largest buyer was Victory Capital Management, adding an estimated $15.5M. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $6.9M.

  • 178 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2023, down from 198 in Q1 2023.
  • Funds reported $843M of Collegium Pharmaceutical stock for Q2 2023, down 9.9% quarter-over-quarter.
  • 16 funds opened new Collegium Pharmaceutical positions in Q2 2023 and 36 closed out, a net change of -20 holders.
  • The largest Collegium Pharmaceutical buyer in Q2 2023 was Victory Capital Management, an estimated $15.5M added.
  • The largest Collegium Pharmaceutical seller in Q2 2023 was Cambridge Investment Research Advisors, an estimated $6.9M sold.

Based on aggregated 13F filings for Q2 2023.